New hope for young hodgkin patients: drug combo aims to cut radiation
NCT ID NCT06563245
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a drug called brentuximab vedotin, combined with chemotherapy, for children, adolescents, and young adults newly diagnosed with classical Hodgkin lymphoma. The goal is to see if this approach can achieve a faster and more complete response, allowing fewer patients to need radiation therapy. About 96 participants will be enrolled, and the study will track how well the cancer responds and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin
What this could lead to
If successful, this could offer a more effective treatment for Hodgkin lymphoma in young people, reducing the need for radiation therapy and its long-term side effects.
What could go wrong
This is an early-phase study with only 96 participants, so results may not apply to everyone. The drug combination may cause side effects, and it's not yet proven to be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China